Immunotherapy Vaccine for Mesothelioma Shows Promise in Combination Treatment
A bacteria-based immunotherapy vaccine for mesothelioma may improve the odds of surviving the disease by boosting the effects of chemotherapy. That is the word from the latest clinical trial of CRS-207 headed by researchers at the National Cancer Institute. Thirty-five inoperable patients received the immunotherapy vaccine for mesothelioma along with standard mesothelioma chemotherapy. Eighty-nine percent of them experienced either a full or partial response to the treatment combination. CRS-207 Immunotherapy Vaccine for Mesothelioma CRS-207 is based on a modified version of Listeria monocytogenes. The bacterium is best known for causing the food borne illness Listeriosis. In CRS-207, the bacteria has been changed so it cannot make patients sick. The immunotherapy vaccine for mesothelioma uses the bacteria to trigger a powerful … Continue reading Immunotherapy Vaccine for Mesothelioma Shows Promise in Combination Treatment
Palliative Radiotherapy for Mesothelioma Produces “Substantial Treatment Response”
Doctors in Pennsylvania may have found a way to boost the effectiveness of palliative radiotherapy for pleural mesothelioma. Palliative radiotherapy is used to help with mesothelioma symptoms. It uses lower doses of radiation. Doctors do not expect to treat mesothelioma with palliative radiotherapy. But researchers at the University of Pennsylvania think it could also be a treatment. They combined palliative radiotherapy with a special kind of gene therapy. The gene therapy affects the immune system. They say the combination produced a “substantial treatment response” in a man with mesothelioma. Immuno-gene Therapy and Palliative Radiotherapy Immuno-gene therapy uses genes to stimulate the immune system against cancer. In the new Pennsylvania case study, a 67-year-old man with mesothelioma received immuno-gene therapy. Doctors … Continue reading Palliative Radiotherapy for Mesothelioma Produces “Substantial Treatment Response”
Chemoimmunotherapy Called “Next Frontier” for Mesothelioma Cancer
Mesothelioma researchers in Australia are calling the combination of chemotherapy and immunotherapy the “next frontier” in the treatment of mesothelioma cancer. In a study published in the journal Expert Opinions in Biological Therapy, the researchers reviewed past clinical trials on mesothelioma immunotherapy. They focused on studies published between 2016 and 2018. Their goal was to get a clearer picture of just how effective these drugs are and how they might be used in combination with other treatments. Chemotherapy for Mesothelioma Cancer Currently, immunotherapy is not the primary treatment for mesothelioma cancer. Instead, most patients have chemotherapy, which is considered the gold standard treatment. For the past 15 years, Alimta has been the main chemotherapy drug for people with malignant mesothelioma. … Continue reading Chemoimmunotherapy Called “Next Frontier” for Mesothelioma Cancer
Combination Mesothelioma Therapy Begins Pivotal Trial
A combination mesothelioma therapy that showed promise in early trials is finally being studied on a larger scale. The power-packed chemo-immuno-gene therapy known as TR002 has the potential to change the outlook for thousands of malignant mesothelioma patients. A small trial of the combination mesothelioma therapy in 2016 produced “significantly higher” mesothelioma survival rates than most patients are told to expect. Drug company Trizell announced last month that the combination will now be tested on 300 patients at sites in the US, Europe, Australia and Russia. Combination Mesothelioma Therapy Starts with Gene Therapy TR002 is an investigational gene therapy for mesothelioma patients who have failed first-line chemotherapy. This combination mesothelioma therapy is based on the human interferon-alpha 2b gene. The … Continue reading Combination Mesothelioma Therapy Begins Pivotal Trial
New Mesothelioma Clinical Trial Will Test Personalized Immunotherapy
A Dutch company has recruited the first patients into a pivotal mesothelioma clinical trial of autologous dendritic cells. Dendritic cells are immune system cells that work as messengers. They help tell T cells to attack cancers like malignant mesothelioma. The new mesothelioma clinical trial will test using the patient’s own dendritic cells (autologous cells) as a way to keep cancer from coming back after mesothelioma treatment. Expanding Mesothelioma Treatment Options There is only one approved treatment for malignant pleural mesothelioma. This “standard of care” treatment is chemotherapy with Alimta (pemetrexed) and cisplatin. Although most mesothelioma patients receive this treatment, very few live longer than a year after diagnosis. A Netherlands-based company called Amphera is trying to change those odds. Its … Continue reading New Mesothelioma Clinical Trial Will Test Personalized Immunotherapy
PARP Inhibitors Could Enhance Immunotherapy Response in Mesothelioma
A new study suggests that drugs known as PARP inhibitors may enhance immunotherapy response in mesothelioma patients. According to a report published in the Journal of Clinical Investigations, PARP inhibitors worked especially well in cancers with mutations in their DNA repair genes. Some malignant mesothelioma patients have mutated DNA repair genes. In these patients, a PARP inhibitor may modify immunotherapy response, making drugs like Keytruda work better. How PARP Impacts Immunotherapy Response PARP stands for poly (ADP-ribose) polymerase. It represents a family of proteins involved in a number of cellular processes, including DNA repair. PARP is also involved in apoptosis, or programmed cell death. Olaparib (Lynparza) is an example of a PARP inhibitor. PARP inhibitors attack tumors that already have … Continue reading PARP Inhibitors Could Enhance Immunotherapy Response in Mesothelioma
Mesothelioma Research Demonstrates Power of Intrapleural Immunotherapy
New metadata suggests that intrapleural immunotherapy is a powerful, targeted way to treat malignant pleural mesothelioma. Pleural mesothelioma is a deadly cancer of the lining around the lungs. It is caused by asbestos exposure and is notoriously difficult to treat. Now, a new study suggests that delivering immunotherapy treatments directly into the pleural space where mesothelioma tumors form may help these drugs work even better. What is Intrapleural Immunotherapy? Immunotherapy treatments harness the immune system to help fight cancer. Immunotherapy works alone or in combination with other treatments like chemotherapy or surgery. Many researchers and doctors believe that immunotherapy is the future of mesothelioma treatment. Intrapleural immunotherapy is a more targeted way to deliver these cancer-fighting messengers. It does … Continue reading Mesothelioma Research Demonstrates Power of Intrapleural Immunotherapy
New Mesothelioma Immunotherapy Treatment Reduces Tregs with Immunotoxin
There is a new mesothelioma immunotherapy treatment in the works. This one is based on reducing the number of Tregs or regulatory T-cells around a mesothelioma tumor. Tregs are an important part of maintaining balance in the immune system. They help protect people against autoimmune diseases like MS and lupus. But in people with malignant mesothelioma and other types of cancer, too many Tregs can be a problem. Tregs respond to distress signals sent out by a tumor. They surround the tumor and protect it against attack from the immune system. The goal of mesothelioma immunotherapy treatment is to reactivate the immune system to fight the cancer. Developing a Mesothelioma Immunotherapy Treatment Molecular biologists at the National Cancer Institute and … Continue reading New Mesothelioma Immunotherapy Treatment Reduces Tregs with Immunotoxin
New Mesothelioma Drug Trial Begins
A new mesothelioma drug trial is now underway. The trial will test a brand new type of immunotherapy medication called CA-170. CA-170 is designed to block an immune system suppressor called VISTA. It is the only VISTA-blocking medication currently in clinical trial. “CA-170 has demonstrated favorable safety and tolerability as well as preliminary anti-tumor activity in patients across multiple tumor types,” the company said in a statement. Mesothelioma Drug Trial Focuses on VISTA Malignant mesothelioma is highly resistant to standard cancer treatments. Many top researchers believe that immunotherapy drugs offer the best promise for curing mesothelioma. That is because cancers like malignant mesothelioma survive in part by evading detection by the immune system. They do this in a variety ways … Continue reading New Mesothelioma Drug Trial Begins
Avelumab May Offer a Second-Line Option for Recurrent Mesothelioma
People with recurrent mesothelioma may get another chance at treatment with the immunotherapy drug avelumab. Malignant mesothelioma is highly resistant to standard cancer therapies. That means that the asbestos cancer usually comes back, or recurs, even after treatment. The most common treatment for mesothelioma is chemotherapy with Alimta. Alimta is the only drug approved specifically for mesothelioma. Patients with recurrent mesothelioma often have several rounds of chemotherapy with Alimta. But once the standard mesothelioma treatments stop working, patients do not have many options. Now a new study suggests that some cases of recurrent mesothelioma that stop responding to Alimta may respond to avelumab. Considering Avelumab for Recurrent Mesothelioma Bavencio is the brand name for avelumab. It is a type … Continue reading Avelumab May Offer a Second-Line Option for Recurrent Mesothelioma
“My Name is Paul Kraus and I Have Survived Mesothelioma for Over 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."
Get your free copy of
“Surviving Mesothelioma” Today!